CNTX - Context Therapeutics Inc

Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of chronic pain. The company is headquartered in Boston, Massachusetts.

52W High

$2.59

52W Low

$0.49

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.91

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.60

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.89

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.33%

Institutions (25–75% balanced)

76.79%

Shares Outstanding

89,704,000

Float

37,696,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-0.43

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.37%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0171

0.0189

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025